Literature DB >> 2825967

In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast.

R Mariani-Costantini1, C Escot, C Theillet, A Gentile, G Merlo, R Lidereau, R Callahan.   

Abstract

We have studied the expression of the c-myc protooncogene and the cycle-dependent histone 4 gene at the cellular level by RNA:RNA in situ hybridization in 18 primary breast ductal adenocarcinomas. These tumors have previously been examined by Southern and Northern blot analysis for the genomic status of c-myc and its expression, respectively (Escot et al., Proc. Natl. Acad. Sci. USA, 83: 4834-4838, 1986). Positive c-myc hybridization signals were associated with carcinoma cells in all cases, including tumors which had no apparent alterations of the c-myc locus. Steady-state levels of c-myc mRNA appeared heterogeneous in carcinomas with similar histology. High levels of hybridization were found in four of seven tumors with strong amplification of the c-myc locus. Similarly high levels of c-myc hybridization were detected in two of nine cases which had an apparently normal c-myc locus but comparatively low cellularity. In addition to carcinoma cells, dense clusters of infiltrating lymphocytes, present in three tumors, exhibited c-myc hybridization. The expression of the histone 4 gene failed to correlate with levels of c-myc expression. We conclude that in infiltrating ductal carcinomas: (a) the c-myc protooncogene is transcriptionally activated; (b) c-myc amplification is probably underestimated due to heterogeneous cellularity; (c) high-level c-myc amplification is related to high-level expression, but other unknown factors also may play a role; (d) differences in levels of c-myc expression may not only be attributed to differences in the growth fractions; and (e) c-myc mRNA in total RNA from biopsy samples may be contributed by infiltrating lymphocytes.

Entities:  

Mesh:

Year:  1988        PMID: 2825967

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Interspecies comparison of c-myc gene in human and rat glioma cell lines.

Authors:  H Shindo; E Tani; N Kochi; K Kaba; T Matsumoto; K Miyaji; Y Yamamoto; J Furuyama
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 2.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

Review 3.  Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer.

Authors:  W J Muller
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

4.  c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue.

Authors:  A McCann; P A Johnston; P A Dervan; W J Gullick; D N Carney
Journal:  Ir J Med Sci       Date:  1989-06       Impact factor: 1.568

Review 5.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

6.  Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas.

Authors:  P Münzel; D Marx; H Köchel; A Schauer; K W Bock
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.

Authors:  N N Nupponen; K Porkka; L Kakkola; M Tanner; K Persson; A Borg; J Isola; T Visakorpi
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 8.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

9.  Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues.

Authors:  Paula L Miliani de Marval; Everardo Macias; Robert Rounbehler; Piotr Sicinski; Hiroaki Kiyokawa; David G Johnson; Claudio J Conti; Marcelo L Rodriguez-Puebla
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

Authors:  Huan Meng; Wilson X Mai; Haiyuan Zhang; Min Xue; Tian Xia; Sijie Lin; Xiang Wang; Yang Zhao; Zhaoxia Ji; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2013-01-04       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.